Which patients have the highest cardiovascular risk? A follow-up study from Turkey

European Journal of Preventive Cardiology

Volumn 12, Issue 3, 2005, Pages 250-256

  Tokgözoälu, Lale ^a   PehlivanoîŸlu, Seã§kin ^b   Kültürsay, Hakan ^c   OÄŸuz, Aytekin ^d   Damci, Taner ^b   Åženocak, Mustafa ^b   Yusuf, Mehmet ^e  

^a HACETTEPE UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c EGE UNIVERSITY   (Turkey)

^d SSK Goztepe Hospital   (Turkey)

^e Clinical Research Organization   (Turkey)

Author keywords

cardiac events; cardiovascular risk factors; Turkey

Indexed keywords

ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG UTILIZATION; FEMALE; FOLLOW UP; HEART INFARCTION; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PERIPHERAL VASCULAR DISEASE; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; REVASCULARIZATION; RISK ASSESSMENT; RISK FACTOR; STROKE; TURKEY (REPUBLIC);

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; ODDS RATIO; RISK FACTORS; TURKEY;

EID: 21344446129     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/01.hjr.0000160723.97540.fd     Document Type: Article

References (12)

1. Sans S, Kesteloot H, Kromhout D, on behalf of the Task Force. The burden of the cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J 1997; 18: 1231–1248.
2. Onat A. Risk factors and cardiovascular disease in Turkey. Atherosclerosis 2001; 156: 1–10.
3. Mahley RW, Palaoglu KE, Atak Z, Dawson-Pepin J, Langlois AM, Cheung V, et al Turkish Heart Study: lipids, lipoproteins and apolipoproteins. J Lipid Res 1995; 36: 839–859.
4. Onat A, Dursunoglu D, Sansoy V. Relatively high coronary death and event rates in Turkish women: relation to three major risk factors in five year follow up of cohort. Int J Cardiol 1997; 61: 69–77.
5. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J 2003; 24: 1601–1610.
6. Greenland P, Deloria Knoll M, Stamler J, Neaton JD, Dyer AR, Garside DB, et al Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 2003; 290: 891–897.
7. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, et al Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003; 290: 898–904.
8. Canto JG, Iskandrian AE. Major risk factors for cardiovascular disease. Debunking the ‘Only 50 %’ myth. JAMA 2003; 290: 947–949.
9. Drouet L. Atherothrombosis as a systemic disease. Cerebrovasc Dis 2002; 13 (Suppl 1): 1–16.
10. Haffner SJ, Cassels H. Hyperglycemia as a cardiovascular risk factor. Am J Med 2003; 115 (Suppl 8A): 6S–11S.
11. Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, et al, for the OASIS Registry Investigators. Impact of diabetes on long term prognosis in patients with unstable angina and nonQ wave myocardial infarction: results of the OASIS registry. Circulation 2000; 102: 1014–1019.
12. Euroaspire Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554–572.